Advancement of the relationship ERCC1 and platinum resistance in digestive system malignant tumors
- VernacularTitle:切除修复交叉互补基因1与消化系统肿瘤铂类耐药的关系研究进展
- Author:
Xiaoqiu LI
;
Bing HU
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Platinum;
Drug resistance;
Nucleotide excision repair;
Tumor
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2000;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Due to the high incidence and mortality of digestive system malignant tumor,so it is of great significance to make further research for digestive tract tumor.Platinum drugs,one of the traditional drugs which is used for the chemotherapy for digestive system tumor,which has been extensively applied to the chemotherapy for malignant tumor.However,the resistance to the drugs exerts a serious influence on its curative effect.At present,it is believed that the nucleotide excision repair(NER)constitutes one of the most important mechanisms which results in the resistance to platinum drugs,mainly because it causes the twisting of DNA helix by removing large numbers of platinum compounds.The nucleotide excision repair cross complementation group 1(ERCC1)plays an important role in the process of NER.The different expression of ERCC1 in peripheral blood and tumor tissue of patients with digestive sysem tumor has a close connection with therapeutic effect of the platinum-containing chemotherapy.This article aims to provide an overview of the relation between the ERCC1 research development and the curative effect of cisplatin chemotherapy for digestive system tumor.
